FreeTheAI

Belite Bio Uplists to Nasdaq Global Select Market Tier

MixedMedium impact
BLTE$142.78 −6.45%

Belite Bio, Inc. (BLTE) announced that its shares have begun trading on the Nasdaq Global Select Market as of October 19, 2026. The clinical-stage drug development company transferred its listing from the Nasdaq Capital Market and will maintain its existing ticker symbol. Shares of the company traded down 6.45% to $142.80 following the transition.

Moving to the Nasdaq Global Select Market, the top tier among Nasdaq market levels, requires meeting stricter financial and liquidity criteria. The company expects the move to improve its visibility with institutional investors, increase trading liquidity, and expand its capital market presence as it advances its financial profile.

Investors will track the ongoing development of Belite Bio's lead oral drug candidate, tinlarebant. The company completed its Phase 3 DRAGON trial for Stargardt disease type 1, meeting the primary endpoint, and is continuing evaluations in the Phase 2/3 DRAGON II study as well as the Phase 3 PHOENIX trial for geographic atrophy in advanced dry age-related macular degeneration.

Key points

  • Belite Bio, Inc. (BLTE) transferred its listing to the Nasdaq Global Select Market on October 19, 2026, under ticker symbol BLTE.
  • The move to Nasdaq's highest market tier follows compliance with stricter financial and liquidity standards.
  • The company aims for the uplisting to increase institutional investor visibility and market recognition.
  • Belite Bio's stock traded at $142.80, down 6.45% on the day.
  • The company is developing tinlarebant for Stargardt disease type 1 and geographic atrophy in advanced dry age-related macular degeneration.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What market tier did Belite Bio move to?

Belite Bio transferred its listing from the Nasdaq Capital Market to the Nasdaq Global Select Market, the highest tier of the Nasdaq market, on October 19, 2026.

Did Belite Bio change its ticker symbol after uplisting?

No, Belite Bio continues to trade under its existing ticker symbol BLTE.

What drugs is Belite Bio developing?

Belite Bio is developing tinlarebant, an oral therapy targeting degenerative retinal conditions including Stargardt disease type 1 and geographic atrophy in advanced dry age-related macular degeneration.